Thursday, August 18, 2016

The State of the Clinical Trials Industry | An Interview with Scott Sawicki, Director of Clinical Procurement Management, Novartis

In this exclusive interview, Scott Sawicki, Director of Clinical Procurement Management at Novartis, joins the Partnerships in Clinical Trials US team to discuss the current trends, biggest concerns, major disruptors, and the role of innovation in clinical trials - as a lead up to the event on October 5-7, in Boston.

Scott is a member of the PCT US advisory board and helped shape this exciting program that brings together the best curated content on clinical trials outsourcing, procurement, operations, and innovation as well as the disruptive technologies that will make your trials faster, better, and more cost-effective. Take a look at Scott's thoughts on the current state of the industry below...

What are the current trends of the clinical trials industry?

SS: Risked based monitoring, the outcomes of this and data review – what are companies doing now that some studies have followed RPM, is there a best practice? Technology with wearables is fairly new and what is the industry going to standardize such devices when wearing? Lack of clarification and consistency with how different sponsors and CROs use the work alliance, collaboration, partnership – there is no standard definition and when these words are used in presentation, the audience is confused.

What are your biggest concerns about the industry?

SS: At some point primary indications will be exhausted, then what? 'Me too' drugs will be on the decline and then what is next with clinical trials, gene mutation? The industry is known to pay high for those who work in it. With many blockbusters going off patent and at some point costs for drugs to be regulated, what will this mean for those who get compensated, with this impact will it be more regulated? How do we as an industry standardize ‘like’ processes across different pharma and CROs in the area where we follow the same processes. There is a lack of standardizing tools and templates for what we do (e.g. RFI/RFP, baselining etc) and finally, how do we standardize certain terms so we all use them the same way consistently, and do not have different definitions for these (e.g. alliance, partnerships, collaborations etc).

What do you see as the biggest disruptor in clinical trials over the next few years?

SS: Technology with wearables. And how this will be implemented consistently in clinical studies.

What role will innovation play in the future of clinical trials?

SS: BIG! Innovation with technology and wearables is already changing the landscape to clinical studies. Companies like Google and Apple are now getting involved in working with pharma and biotech in this space and it is only going to get bigger.

Don't miss out! Be sure to join Scott this October 5-7 at Partnerships in Clinical Trials US. Use the VIP code "P2100BLOG" to save $100 off your registration. Click here to learn more.

No comments: